Nigel Lange, CEO & Managing Director of OncoSil Medical, said:

"Being selected to participate in PALACROS is an important validation for OncoSil. What makes this opportunity particularly significant is that PALACROS, which is funded via a grant from the European Union, is an academically driven European consortium bringing together a select group of the world's leading pancreatic cancer centres. The inclusion of OncoSil™ in this initiative e reflects growing independent clinical interest in our technology and its potential role within future multimodal treatment strategies for locally advanced pancreatic cancer. The dedicated PULSE study provides an important opportunity to evaluate the potential of repeat OncoSil™ treatment in a robust multicentre academic setting, while contributing to one of Europe's most ambitious collaborative pancreatic cancer research programs."